Core Insights - NextCure, Inc. presented preclinical data showing that NC605, an anti-Siglec-15 antibody, enhances bone quality and mechanical properties in a model of Osteogenesis Imperfecta (OI) [1][4] Group 1: Company Overview - NextCure is a clinical-stage biopharmaceutical company focused on developing innovative therapies for cancer patients who do not respond to existing treatments [5] - The company utilizes differentiated mechanisms of action, including antibody-drug conjugates and proteins, to advance its therapeutic candidates [5] Group 2: Osteogenesis Imperfecta (OI) Insights - OI is characterized by high bone turnover, abnormal bone formation, and increased fragility, with no current cure available [2] - Existing treatments primarily inhibit bone loss but result in poor bone quality, whereas NC605 enhances osteoblast recruitment and improves bone quality [2] Group 3: Preclinical Data Findings - In a study with OI mice, 90% of treated male and 80% of treated female mice had no fractures, compared to 85% and 55% in control groups, respectively [3] - Treated mice exhibited increased trabecular and cortical tissue mineral density, leading to enhanced overall bone quality [3] - Specifically, treated male mice showed increased trabecular bone volume fraction and cortical thickness, resulting in improved mechanical strength measures [3][4]
Preclinical Data Demonstrates Anti-Siglec-15 Treatment Enhanced Generation of Quality Bone with Better Mechanical Properties in Mice with Moderate-to-Severe Osteogenesis Imperfecta